1197013-81-2

Upstream product

• 582333-07-1 tert-butyl N-[(1s,4s)-4-(2-chloro-5-fluoronicotinamido)cyclohexyl]carbamate 
• 247570-24-7 tert-butyl N-[(1s,4s)-4-aminocyclohexyl]carbamate 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 1196806-69-5 tert-butyl N-[(1s,4s)-4-[5-fluoro-2-(3-iodophenoxy)nicotinamido]cyclohexyl]carbamate 

Downstream Products

• 1197291-10-3 N-((1s,4s)-4-(5-fluoro-2-(3-iodophenoxy)nicotinamido)cyclohexyl)-2-methylthiazole-4-carboxamide 
• 1197291-15-8 N-((1s,4s)-4-(5-fluoro-2-(3-iodophenoxy)nicotinamido)cyclohexyl)-5-methylimidazo[1,2-a]pyridine-2-carboxamide 
• 1197291-40-9 C₃₃H₃₆FN₅O₆S 
• 1197291-16-9 N-((1s,4s)-4-(5-fluoro-2-(4'-formylbiphenyl-3-yloxy)nicotinamido)cyclohexyl)-5-methylimidazo[1,2-a]pyridine-2-carboxamide 
• 1197291-24-9 N-((1s,4s)-4-(1,5-dimethyl-1H-pyrazole-3-carboxamido)cyclohexyl)-5-fluoro-2-(4'-formylbiphenyl-3-yloxy)nicotinamide 
• 1197291-17-0 N-((1s,4s)-4-(5-fluoro-2-(4'-formylbiphenyl-3-yloxy)nicotinamido)cyclohexyl)-2-methylthiazole-4-carboxamide 
• 1197291-32-9 N-((1s,4s)-4-(1,5-dimethyl-1H-pyrazole-3-carboxamido)cyclohexyl)-5-fluoro-2-(3'-formylbiphenyl-3-yloxy)nicotinamide 
• 1197291-35-2 N-((1s,4s)-4-(1,5-dimethyl-1H-pyrazole-3-carboxamido)cyclohexyl)-5-fluoro-2-(3'-formyl-4'-hydroxybiphenyl-3-yloxy)nicotinamide 
• 1197291-26-1 N-((1s,4s)-4-(1,5-dimethyl-1H-pyrazole-3-carboxamido)cyclohexyl)-5-fluoro-2-(3'-formyl-5'-hydroxybiphenyl-3-yloxy)nicotinamide 
• 1197291-36-3 N-((1s,4s)-4-(1,5-dimethyl-1H-pyrazole-3-carboxamido)cyclohexyl)-5-fluoro-2-(3'-formyl-2'-hydroxybiphenyl-3-yloxy)nicotinamide 
• 1197291-87-4 C₃₄H₃₈FN₅O₆S 
• 1197291-57-8 C₃₃H₃₆FN₅O₆S 
• 1628847-93-7 N-((1s,4s)-4-(5-fluoro-2-(4'-((4-(pyrrolidin-1-yl)piperidin-1-yl)methyl)biphenyl-3-yloxy)nicotinamido)cyclohexyl)-5-methylimidazo[1,2-a]pyridine-2-carboxamide trifluoroacetic acid salt 
• 1197289-47-6 N-((1s,4s)-4-(2-(4'-((dimethylamino)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-2-methylthiazole-4-carboxamide trifluoroacetic acid salt 

Relevant academic research and scientific papers

Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD

Oral phosphodiesterase 4 (PDE4) inhibitors, such as cilomilast and roflumilast, have been shown to be efficacious against chronic obstructive pulmonary disease (COPD). However, these drugs have been hampered by mechanism-related side effects such as nause